Skip to content
Back to news
MarketNovember 19, 2026

Pfizer to Pay $330M Upfront to Enter In Vivo CAR-T With Starna

Pfizer to Pay $330M Upfront to Enter In Vivo CAR-T With Starna: PharmoniQ news card

Pfizer has agreed to license three early autoimmune programs from China's Starna Therapeutics. The deal is worth up to $2.6 billion. BioPharma Dive said it would be Pfizer's first venture into this area of research, known as in vivo CAR-T, a way of reprogramming immune cells inside the body.

What happened

Pfizer announced the exclusive licensing agreement on Nov. 18. According to Reuters, Pfizer will pay Starna $330 million upfront. Up to $2.3 billion more depends on development, regulatory and sales milestones. Starna is also eligible for royalties if any product reaches the market.

The key terms reported so far:

  • Programs: three autoimmune disease candidates that have not yet been tested in people, Reuters reported.
  • Territory: Pfizer gets the rights outside Greater China, with options to add Greater China later.
  • Wider rights: Pfizer can also use Starna's technology in inflammation, immunology and oncology, and holds options to license other Starna projects, BioPharma Dive reported.
  • Manufacturing: supplies for the first clinical trials will be made at Pfizer's US facilities.

Why it matters

Approved CAR-T cancer therapies, such as J&J's Carvykti, are made outside the body. A patient's cells are collected, changed outside the body and then returned, usually alongside chemotherapy conditioning. Starna's approach uses RNA-based medicines meant to change immune cells while they are still in the patient. Companies in the field want to cut out much of that manufacturing work and avoid the chemotherapy.

Pfizer highlighted its experience with RNA medicines, including its Comirnaty COVID-19 vaccine.

The field is crowded. BioPharma Dive listed AstraZeneca, AbbVie, Gilead Sciences and Bristol Myers Squibb as buyers of companies working on the technology over the last two years. Separately, safety concerns recently led Novartis and Bristol Myers to pause some CAR-T studies in autoimmune disease. The report did not say whether those were in vivo programs.

The deal also adds to Pfizer's links with China. By BioPharma Dive's count, Pfizer has formed at least five major partnerships with Chinese companies since January 2025. Reuters said it follows Pfizer's $10.5 billion agreement with Innovent Biologics in May and an earlier deal with 3SBio. Reuters added that Pfizer wants to restart growth by 2028 as many of its patents near expiry and COVID-related sales keep falling.

What it means for people in the industry

The clearest US angle is manufacturing. Pfizer plans to make early trial supplies at its own US sites, so at least some of the first production work will happen in the US. The reports do not say whether the deal will add jobs.

For people in immunology and cell therapy, Pfizer now joins AstraZeneca, Bristol Myers Squibb and other large drugmakers that have made in vivo cell therapy deals in the last two years. Watch for when the first Starna programs enter human trials, and whether Pfizer uses its options on other projects or on Greater China. Licensing teams should also note that Pfizer keeps striking major deals with Chinese drug developers.

This article reports business news only. It is not medical advice.

See open pharma jobs in the US and Canada

Sources

Check Your Supplement Interactions

Use our AI-powered checker to analyze supplement safety and interactions.

Open Interaction Checker →

Comments (0)

Leave a comment

Your email is not shown. Please keep it civil and do not give medical advice. Comment rules

This article is for informational purposes only and does not constitute medical or investment advice. It was written with AI assistance from the sources listed above. Check the original sources before relying on any detail.